

PATENT
674525-2001AMENDMENT

It is respectfully requested that the application be amended without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

IN THE CLAIMS

Please add the following claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

48. (New) A method of reducing T-cell activation by administering a Notch ligand comprising a DSL domain to a patient in need thereof, wherein the Notch ligand is Serrate.

49. (New) The method of claim 48 wherein the T-cell activation occurs with one or more conditions selected from the group consisting of allergy, autoimmunity and graft rejection.

50. (New) A method of reducing T-cell activation by administering a Notch ligand comprising a DSL domain to a patient in need thereof, wherein the Notch ligand is Delta.

51. (New) The method of claim 50 wherein the T-cell activation occurs with one or more conditions selected from the group consisting of allergy, autoimmunity and graft rejection.

Please cancel claims 7-25, 32 and 40-47 without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents. Applicants retain the right to file divisional applications to non-elected subject matter.